Novartis AG (NVS)

NYSE: NVS · IEX Real-Time Price · USD
+0.89 (0.92%)
At close: Nov 30, 2023, 4:00 PM
-0.69 (-0.70%)
After-hours: Nov 30, 2023, 7:58 PM EST
Market Cap 201.23B
Revenue (ttm) 52.32B
Net Income (ttm) 7.84B
Shares Out 2.06B
EPS (ttm) 3.73
PE Ratio 25.10
Forward PE 13.81
Dividend $3.47 (3.54%)
Ex-Dividend Date Mar 9, 2023
Volume 1,021,122
Open 96.88
Previous Close 97.01
Day's Range 96.73 - 97.91
52-Week Range 79.98 - 105.61
Beta 0.51
Analysts Hold
Price Target n/a
Earnings Date Oct 24, 2023

About NVS

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated ... [Read more]

Sector Healthcare
IPO Date Nov 18, 1991
Employees 101,703
Stock Exchange NYSE
Ticker Symbol NVS
Full Company Profile

Financial Performance

In 2022, Novartis AG's revenue was $51.83 billion, a decrease of -1.98% compared to the previous year's $52.88 billion. Earnings were $6.96 billion, a decrease of -71.05%.

Financial Statements


Novartis aims for 5% annual sales growth through 2027

Novartis said it was targeting annual sales growth of 5% per year until 2027 and a core operating income margin of about 40% by 2027, driven by innovative drugs on the market, after it severed ownersh...

2 days ago - Reuters

Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day

Ad hoc announcement pursuant to Art. 53 LR  ‘Pure-play' innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent growth Mid-t...

2 days ago - GlobeNewsWire

Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH

Basel, November 20, 2023 — Novartis will present data from over 100 trials across its breast cancer and hematology portfolios at the 2023 San Antonio Breast Cancer Symposium (SABCS) and the American S...

10 days ago - GlobeNewsWire

Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2

Basel, November 9, 2023 — Novartis today announced new positive data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib – a highly selective, oral Bruton's tyrosine kinase (BTK)...

21 days ago - GlobeNewsWire

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

Basel, October 31, 2023 — Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat...

4 weeks ago - GlobeNewsWire

Novartis says drug candidate is successful in rare kidney disease trial

Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug...

4 weeks ago - Reuters

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Ad hoc announcement pursuant to Art. 53 LR Phase III ALIGN study met its primary endpoint, demonstrating superiority of atrasentan vs.

4 weeks ago - GlobeNewsWire

Novartis Raises Outlook After Sandoz Generics Spinoff

Novartis CEO Vas Narasimhan discusses third-quarter results with the company lifting its profit forecast for a third time as he calls the drugmaker a pure-play innovative medicines “powerhouse.” He sp...

5 weeks ago - Bloomberg Markets and Finance

Novartis Begins New Era With Profit Beat and Guidance Hike

The Swiss pharmaceutical company says its transition to a pure-play innovative medicines business is now complete following the spinoff of Sandoz, its generic drugs unit.

5 weeks ago - Barrons

Novartis lifts 2023 earnings forecast for third time

Novartis on Tuesday raised its full-year earnings forecast for the third time on strong drug sales, after its generic drugs business Sandoz was spun off and listed on Oct 4.

5 weeks ago - Reuters

Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance

Ad hoc announcement pursuant to Art. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing operations 2 Q 3 ...

5 weeks ago - GlobeNewsWire

Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting

Basel, October 23, 2023 — Novartis today presents data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology (ESMO) Congress. Data presented at the Presidential Symposium...

5 weeks ago - GlobeNewsWire

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer

Basel, October 20, 2023 — Novartis will present late-breaking results from a prespecified exploratory subgroup analysis of invasive disease-free survival (iDFS) from the pivotal Phase III NATALEE tria...

5 weeks ago - GlobeNewsWire

Eli Lilly, McKesson, Novartis Flash Promising Chart Action

Although healthcare stocks lag other sectors, large-cap leaders such as  Eli Lilly & Co. NYSE: LLY, McKesson Corp. NYSE: MCK and Novartis AG NYSE: NVS  are in possible buy ranges as they get moving-av...

Other symbols: LLYMCK
7 weeks ago - MarketBeat

Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer

Basel, October 5, 2023 — Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developme...

2 months ago - GlobeNewsWire

Novartis CEO: Spinoffs will see us succeed as a pure-play innovative medicines company

Novartis CEO Vas Narasimhan discusses what the spinoff of the company's Sandoz unit means for the organization.

2 months ago - CNBC International TV

Novartis unit Sandoz set to start trading after completing spinoff

Novartis has completed the planned spin-off of its generics and biosimilars business, Sandoz, which will begin trading on the SIX Swiss Exchange on Wednesday.

2 months ago - CNBC

Novartis completes Sandoz spinoff

Novartis has completed the planned spin-off of its generics and biosimilars business Sandoz , the Swiss drugmaker said in a statement on Wednesday.

2 months ago - Reuters

Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines

Basel, October 4, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today celebrates the start of share trading on the SIX Swiss Exchange as an independent company.

2 months ago - GlobeNewsWire

Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company

Ad hoc announcement pursuant to Art. 53 LR  Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off Shares of Sandoz will be listed and commence ...

2 months ago - GlobeNewsWire

Novartis positioning is now best-suited for long-term gains and returns after spin-off, says CEO

Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the company's new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the company's gr...

2 months ago - CNBC Television

Novartis CEO: Company set to become a pure play, innovative medicine business after Sandoz spin off

Vas Narasimhan, CEO at Novartis, discusses the company's 100% spin off of Sandoz, its generic and biosimilar medicines business, and what the deal means for shareholders.

2 months ago - CNBC International TV

Novartis considers selling radiopharma unit's assets - Bloomberg News

Novartis AG is considering selling a part of its radiopharmaceuticals business, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.

2 months ago - Reuters

Drugmakers opt in to Medicare drug price negotiations – here's what happens next

The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.

2 months ago - CNBC

Drugmakers sign on to negotiate Medicare prices under protest

All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to part...

2 months ago - Reuters